Increased Frequency of Clonal Hematopoiesis of Indeterminate Potential in Bloom Syndrome Probands and Carriers
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Bloom Syndrome patients and BLM variant carriers show increased clonal hematopoiesis, suggesting a link between BLM variants and cancer risk. Further research is needed to confirm CHIP as a biomarker.
Area Of Science
- Genetics and Genomics
- Cancer Biology
- Hematology
Background
- Bloom Syndrome (BSyn) is an inherited disorder linked to BLM gene variants, causing genomic instability and increased cancer risk.
- Individuals with BSyn experience growth issues, immune deficiencies, and insulin resistance, with a high incidence of hematologic malignancies.
- The cancer risk in carriers of pathogenic BLM variants is not well understood, despite the known association with Clonal Hematopoiesis of Indeterminate Potential (CHIP).
Approach
- Exome sequencing was performed on Bloom Syndrome patients and their parents (trios) compared to control trios.
- The study aimed to identify an increase in de novo or somatic variations in BSyn patients and BLM variant carriers.
- Analysis focused on detecting somatic mutations in genes associated with CHIP and DNA methylation.
Key Points
- Both BSyn patients and BLM variant carriers exhibited a higher number of low-frequency somatic variants in CHIP genes compared to controls.
- BLM variant carriers showed an increased number of somatic variants in DNA methylation genes.
- No significant difference in de novo variants was observed between BSyn probands and control probands.
Conclusions
- Increased CHIP in BSyn patients and carriers suggests that BLM variants may predispose individuals to clonal hematopoiesis.
- These findings highlight the potential role of CHIP as a biomarker for aging, cancer, and cardiovascular disease.
- Larger cohort studies are recommended to validate the significance of CHIP in relation to health outcomes and mortality.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Commitment is the process whereby stem cells:
lose their ability to form all cell types and
irreversibly change into a specific type.
The multipotent hematopoietic stem cells, (HSCs), differentiate into the multipotent hematopoietic progenitor cells, (HPCs). The HPCs express many lineage-specific cytokine receptors. Each of these receptors binds specific cytokines, activates distinct signaling pathways, and expresses a particular gene set. The HPCs further differentiate to...
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...